Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 trial of intradiscal allogeneic BM-MSC therapy versus sham control for chronic low back pain due to lumbar degenerative disc disease
2023-510000-45-00Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MSV allogeneic bone marrow-derived mesenchymal stromal cells in lumbosacral disc disease (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoints: Clinical response at month 12, Change in disc fluid content and 1 more. Started Nov 2024; status: completed.
02
Drugs
MSV allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
lumbosacral disc disease
Beyond the preview
Go deeper on 2023-510000-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510000-45-00.